Maze Therapeutics (NASDAQ:MAZE) Insider Sells $84,350.43 in Stock

Key Points

• Maze Therapeutics insider Atul Dandekar sold 3,243 shares for $84,350 at an average price of $26.01, reducing his position by 9.12%. The sale was made to cover tax withholding from vested equity awards.
• MAZE shares rose 1.3% to $26.21 but remain below their 50-day and 200-day moving averages of $28.74 and $31.20, respectively. The company reported a quarterly loss of $0.76 per share, with analysts expecting a full-year loss of about $2.72 per share.
• Analyst sentiment is generally positive, with a consensus “Buy” rating and a $66 average price target, although repeated insider selling and the company’s ongoing losses may weigh on investor sentiment.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Atul Dandekar sold 3,243 shares of the company's stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total value of $84,350.43. Following the transaction, the insider owned 32,316 shares of the company's stock, valued at approximately $840,539.16. This represents a 9.12% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Atul Dandekar also recently made the following trade(s):

• On Wednesday, September 2nd, Atul Dandekar sold 3,191 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.47, for a total transaction of $84,465.77.
• On Friday, August 28th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.58, for a total transaction of $206,850.00.
• On Wednesday, July 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.34, for a total transaction of $205,050.00.
• On Monday, June 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The stock was sold at an average price of $28.02, for a total transaction of $210,150.00.

Maze Therapeutics Trading Up 1.3%

Shares of NASDAQ:MAZE traded up $0.34 on Friday, hitting $26.21. The company had a trading volume of 273,266 shares, compared to its average volume of 637,671. The firm's 50-day simple moving average is $28.74 and its two-hundred day simple moving average is $31.20. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of -10.40 and a beta of 2.17. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. Maze Therapeutics, Inc. has a 1 year low of $14.27 and a 1 year high of $53.65.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). Equities analysts anticipate that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

More Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on MAZE. Weiss Ratings reissued a "sell (d-)" rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. TD Cowen upgraded Maze Therapeutics to a "strong-buy" rating in a research report on Monday, August 24th. BTIG Research reaffirmed a "buy" rating and issued a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, August 12th. Finally, Wall Street Zen downgraded Maze Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $66.00.

Institutional Investors Weigh In On Maze Therapeutics

Several hedge funds have recently bought and sold shares of the business. Royal Bank of Canada grew its holdings in Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company's stock worth $27,000 after purchasing an additional 363 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in shares of Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock valued at $42,000 after purchasing an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Maze Therapeutics in the 4th quarter worth approximately $43,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Maze Therapeutics in the 2nd quarter worth approximately $48,000. Finally, Russell Investments Group Ltd. boosted its position in shares of Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company's stock worth $49,000 after purchasing an additional 1,725 shares in the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source